JP2023535163A - Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法 - Google Patents

Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法 Download PDF

Info

Publication number
JP2023535163A
JP2023535163A JP2023503013A JP2023503013A JP2023535163A JP 2023535163 A JP2023535163 A JP 2023535163A JP 2023503013 A JP2023503013 A JP 2023503013A JP 2023503013 A JP2023503013 A JP 2023503013A JP 2023535163 A JP2023535163 A JP 2023535163A
Authority
JP
Japan
Prior art keywords
cov
sars
seq
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535163A5 (enExample
Inventor
ピエール・シャルノー
ミン－ウェン・ク
ピエール・オーティエ
ニコラ・エスクリウ
マリリーヌ・ブルジーヌ
ラレー・マジレッシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravectys SA
Original Assignee
Theravectys SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000293 external-priority patent/WO2022167831A1/en
Application filed by Theravectys SA filed Critical Theravectys SA
Publication of JP2023535163A publication Critical patent/JP2023535163A/ja
Publication of JP2023535163A5 publication Critical patent/JP2023535163A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023503013A 2020-07-15 2021-07-15 Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法 Pending JP2023535163A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063052264P 2020-07-15 2020-07-15
US63/052,264 2020-07-15
US202063130202P 2020-12-23 2020-12-23
US63/130,202 2020-12-23
IBPCT/IB2021/000293 2021-02-02
PCT/IB2021/000293 WO2022167831A1 (en) 2021-02-02 2021-02-02 Sars-cov-2 immunogenic compositions, vaccines, and methods
PCT/EP2021/069890 WO2022013405A1 (en) 2020-07-15 2021-07-15 Sars-cov-2 immunogenic compositions, vaccines, and methods

Publications (2)

Publication Number Publication Date
JP2023535163A true JP2023535163A (ja) 2023-08-16
JP2023535163A5 JP2023535163A5 (enExample) 2024-07-24

Family

ID=77104030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503013A Pending JP2023535163A (ja) 2020-07-15 2021-07-15 Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法

Country Status (8)

Country Link
US (1) US20230256084A1 (enExample)
EP (1) EP4181954A1 (enExample)
JP (1) JP2023535163A (enExample)
KR (1) KR20230041028A (enExample)
AU (1) AU2021308424A1 (enExample)
BR (1) BR112023000730A2 (enExample)
CA (1) CA3185952A1 (enExample)
WO (1) WO2022013405A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117120085A (zh) * 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
WO2023135439A1 (en) * 2022-01-17 2023-07-20 Institut Pasteur Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
EP4486378A1 (en) * 2022-03-02 2025-01-08 ISR Immune System Regulation Holding AB (publ) Vaccine composition comprising an antigen and a tlr3 agonist
PL442478A1 (pl) * 2022-10-10 2024-04-15 Politechnika Warszawska Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych
PL247223B1 (pl) * 2022-10-10 2025-06-02 Politechnika Warszawska Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych
WO2024091694A1 (en) * 2022-10-28 2024-05-02 Mary Hitchcock Memorial Hospital, For Itself And On Behalf Of Dartmouth-Hitchcock Clinic Chimeric human receptor for pathogenic viruses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049752A1 (ja) * 2005-10-28 2007-05-03 Dnavec Corporation Rnaウイルスまたはdnaウイルスのスパイクタンパク質でシュードタイプ化したレンチウイルスベクターを用いた気道上皮幹細胞への遺伝子導入
JP2013500015A (ja) * 2009-07-24 2013-01-07 イミューン デザイン コーポレイション シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
WO2017182607A1 (en) * 2016-04-21 2017-10-26 Genethon Stable pseudotyped lentiviral particles and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049752A1 (ja) * 2005-10-28 2007-05-03 Dnavec Corporation Rnaウイルスまたはdnaウイルスのスパイクタンパク質でシュードタイプ化したレンチウイルスベクターを用いた気道上皮幹細胞への遺伝子導入
JP2013500015A (ja) * 2009-07-24 2013-01-07 イミューン デザイン コーポレイション シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
WO2017182607A1 (en) * 2016-04-21 2017-10-26 Genethon Stable pseudotyped lentiviral particles and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 180, JPN6025031400, March 2020 (2020-03-01), pages 281 - 292, ISSN: 0005793099 *
FRONT IMMUNOL., vol. 9, JPN6025031403, 2018, pages 171 - 1, ISSN: 0005793098 *
J. VIROL., vol. 94, JPN6025031402, March 2020 (2020-03-01), pages 00127 - 20, ISSN: 0005793101 *
LIFE SCI., vol. 257, JPN6025031401, 6 July 2020 (2020-07-06), pages 1 - 7, ISSN: 0005793100 *
VIRUSES, vol. 12, JPN6026004344, May 2020 (2020-05-01), pages 1 - 15, ISSN: 0005793102 *

Also Published As

Publication number Publication date
AU2021308424A1 (en) 2023-02-09
EP4181954A1 (en) 2023-05-24
KR20230041028A (ko) 2023-03-23
BR112023000730A2 (pt) 2023-10-03
WO2022013405A1 (en) 2022-01-20
CA3185952A1 (en) 2022-01-20
US20230256084A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
US20230023093A1 (en) Dna antibody constructs and method of using same
JP2023535163A (ja) Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法
JP6480028B2 (ja) レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用
US20220112273A1 (en) DNA Antibody Constructs And Method Of Using Same
US20230021583A1 (en) Measles-vectored covid-19 immunogenic compositions and vaccines
KR101790187B1 (ko) 신드비스 바이러스 외피 당단백질로 가성형태화된 렌티바이러스 벡터
JP5123343B2 (ja) Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
US20250090655A1 (en) Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
EP2020444B1 (en) Defective non-integrative lentiviral transfer vectors for vaccines
JP2017534284A (ja) 最適化ＨＩＶ遺伝子を含有及び発現する遺伝的に安定な複製可能センダイ（Ｓｅｎｄａｉ）ウイルスベクター
WO2022167831A1 (en) Sars-cov-2 immunogenic compositions, vaccines, and methods
Ku et al. Intranasal vaccination with a lentiviral vector strongly protects against SARS-CoV-2 in mouse and golden hamster preclinical models
JP2024509976A (ja) 抗原をｍｈｃ－ｉｉ経路にターゲティングし、宿主におけるｃｄ８＋及びｃｄ４＋ｔ細胞による防御免疫を誘導するレンチウイルスベクター
KR20240049802A (ko) 결핵 백신
TW202423456A (zh) 表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
Gallinaro Integrase defective lentiviral vector as a vaccine platform for delivering HIV-1 antigens
CN118510791A (zh) 结核疫苗
Center et al. Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates
HK40007688A (en) Lentiviral vectors for expression of hepatitis b virus (hbv) antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210